Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BPTHNASDAQ:GRTXNASDAQ:ONCTNASDAQ:OTIC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBPTHBio-Path$0.16-7.4%$0.17$0.12▼$3.39$1.35M-0.05989,516 shs36,334 shsGRTXGalera Therapeutics$0.03+1.8%$0.03$0.02▼$0.15$2.19M1.8796,911 shs43,224 shsONCTOncternal Therapeutics$0.53$0.53$0.53▼$7.83$1.56M1.1884,462 shsN/AOTICOtonomy$0.01$0.06$0.01▼$2.54$582K1.54937,525 shsN/A10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBPTHBio-Path-7.43%-14.51%-14.74%+4.52%-91.73%GRTXGalera Therapeutics+1.75%+3.57%+21.34%-10.77%-78.53%ONCTOncternal Therapeutics0.00%0.00%0.00%0.00%-93.16%OTICOtonomy0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBPTHBio-Path1.8273 of 5 stars3.53.00.00.00.00.01.3GRTXGalera Therapeutics0.2338 of 5 stars0.03.00.00.00.61.70.0ONCTOncternal TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AOTICOtonomyN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBPTHBio-Path 3.00Buy$20.0012,245.68% UpsideGRTXGalera Therapeutics 0.00N/AN/AN/AONCTOncternal Therapeutics 2.25Hold$10.001,798.97% UpsideOTICOtonomy 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBPTHBio-PathN/AN/AN/AN/A$0.71 per shareN/AGRTXGalera TherapeuticsN/AN/AN/AN/A($2.41) per shareN/AONCTOncternal Therapeutics$790K1.97N/AN/A$10.19 per share0.05OTICOtonomy$130K4.48N/AN/A$0.97 per share0.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBPTHBio-Path-$16.08MN/A0.00N/AN/AN/A-2,842.40%-337.48%8/13/2025 (Estimated)GRTXGalera Therapeutics-$59.08M-$0.35N/A∞N/AN/AN/A-99.34%8/12/2025 (Estimated)ONCTOncternal Therapeutics-$39.48M-$11.69N/AN/AN/A-1,599.95%-177.58%-131.30%N/AOTICOtonomy-$51.18M-$0.77N/A∞N/AN/A-137.86%-68.50%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBPTHBio-PathN/AN/AN/AN/AN/AGRTXGalera TherapeuticsN/AN/AN/AN/AN/AONCTOncternal TherapeuticsN/AN/AN/AN/AN/AOTICOtonomyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBPTHBio-PathN/A0.860.86GRTXGalera TherapeuticsN/A9.749.74ONCTOncternal TherapeuticsN/A2.392.39OTICOtonomyN/A1.741.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBPTHBio-Path5.74%GRTXGalera Therapeutics50.77%ONCTOncternal Therapeutics16.05%OTICOtonomy41.23%Insider OwnershipCompanyInsider OwnershipBPTHBio-Path0.72%GRTXGalera Therapeutics12.90%ONCTOncternal Therapeutics11.20%OTICOtonomy1.09%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBPTHBio-Path108.31 million5.73 millionOptionableGRTXGalera Therapeutics3075.46 million47.38 millionOptionableONCTOncternal Therapeutics302.96 million2.63 millionNo DataOTICOtonomy5168.53 million67.78 millionOptionableOTIC, GRTX, ONCT, and BPTH HeadlinesRecent News About These CompaniesOtonomy's hearing loss drug shows no benefit in trial, tanking sharesSeptember 3, 2024 | pharmaphorum.comPTop 8 Best Antibiotic for Dog Ear Infection: Top Picks and How to Use Them in 2023April 21, 2024 | straight.comSAllergic Contact Dermatitis and Topical AntibioticsSeptember 10, 2023 | medscape.comMHearing Loss in AdultsAugust 21, 2023 | nejm.orgNResearch PublicationsAugust 4, 2023 | slu.eduSManagement of Pediatric Otitis MediaMay 11, 2023 | medscape.comMHearing Loss Pipeline Analysis Demonstrates 35+ Key Companies at the Horizon Expected to Transform the Treatme - openPRMay 8, 2023 | news.google.comNAlluvial Capital Management Q1 2023 Letter To Partners - Seeking AlphaApril 28, 2023 | news.google.comNVertigo Treatments Market Forecast: Analysis and Insights for 2023 ... - Digital JournalApril 27, 2023 | news.google.comNHearing Loss Clinical Trial Pipeline Insights Featuring 32+ Companies - openPRApril 25, 2023 | news.google.comNENT Disorder Treatment Market to grow at a CAGR of over 3.3 ... - Digital JournalApril 24, 2023 | news.google.comNHearing Loss Clinical Trials 2023 (Updates): FDA Approvals ... - Digital JournalApril 11, 2023 | news.google.comNENT Disorder Treatment Market : Factors Benefitting Emergence of ... - Digital JournalApril 10, 2023 | news.google.comN[Research Report] Hearing Loss Disease Treatment Market Improve ... - Digital JournalApril 10, 2023 | news.google.comNHearing Loss Emerging and Marketed Drugs Assessment (2023 ... - Digital JournalApril 3, 2023 | news.google.comNHearing-focused biotech grabs trio of programs from Otonomy's fire ... - Endpoints NewsMarch 30, 2023 | news.google.comNAlector cuts 11% of workforce as it doubles down on late-stage ... - Endpoints NewsMarch 30, 2023 | news.google.comNMathai Mammen hands in J&J's R&D keys to lead Greg Verdine's ... - Endpoints NewsMarch 30, 2023 | news.google.comNBoehringer reports robust sales led by type 2 diabetes and ... - Endpoints NewsMarch 30, 2023 | news.google.comNSeelos Therapeutics 'temporarily' stops study in rare neuro disorder ... - Endpoints NewsMarch 30, 2023 | news.google.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeAnalyst Sees Meta Hitting $800: What May Lead Shares to New HighsBy Leo Miller | June 24, 2025View Analyst Sees Meta Hitting $800: What May Lead Shares to New HighsOTIC, GRTX, ONCT, and BPTH Company DescriptionsBio-Path NASDAQ:BPTH$0.16 -0.01 (-7.43%) As of 06/26/2025 03:59 PM EasternBio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.Galera Therapeutics NASDAQ:GRTX$0.03 +0.00 (+1.75%) As of 06/26/2025 02:48 PM EasternGalera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy. It also develops rucosopasem manganese (rucosopasem) to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.Oncternal Therapeutics NASDAQ:ONCT$0.53 0.00 (0.00%) As of 04/29/2025Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. is headquartered in San Diego, California.Otonomy NASDAQ:OTICOtonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside Is IBM’s AI Transformation Powering a Sustained Rally? Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst Amazon: Why Some Are Growing Bearish, and Why They’re Wrong ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside Astera Labs: AI Infrastructure Play With Significant Growth Ahead Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
